Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Follicular 1Hypertension 1

Interventions

Rituximab 3fludarabine phosphate 2Etoposide 2Cyclophosphamide 2umbralisib 1ublituximab 1remdesivir 1fludarabine 1epratuzumab 1aldesleukin 1Whole-Body Irradiation 1UE2343 1Transplantation, Homologous 1Transplantation, Autologous 1Thiotepa 1Therapeutics 1Tacrolimus 1Standard of Care 1Sildenafil Citrate 1Radiotherapy 1Radioimmunodetection 1Methotrexate 1Melphalan 1Hydrochlorothiazide 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Drug Therapy 1Dosage Forms 1Carmustine 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Lymphoma, Follicular × Amlodipine × Clear all
NCT02072330 2014-02-26

Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.

Takeda

Phase 2/3 Completed
353 enrolled
Lymphoid

Hypertension, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡